Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CCX140-B safety and efficacy in adults with type 2 diabetes mellitus
ISRCTN54010405Phase 2Completed
- Sponsor
- ChemoCentryx
- Start
- Jan 2010
- Modality
- Small Molecules
01
Overview
Phase 2, randomised trial of ilacirnon in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by ChemoCentryx. Primary endpoint: Incidence of adverse events. Started Jan 2010; status: completed.
02
Drugs
ilacirnon
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ISRCTN54010405.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN54010405.